CA2504280A1 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents

Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Download PDF

Info

Publication number
CA2504280A1
CA2504280A1 CA002504280A CA2504280A CA2504280A1 CA 2504280 A1 CA2504280 A1 CA 2504280A1 CA 002504280 A CA002504280 A CA 002504280A CA 2504280 A CA2504280 A CA 2504280A CA 2504280 A1 CA2504280 A1 CA 2504280A1
Authority
CA
Canada
Prior art keywords
epa
dha
content
mixture
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504280A
Other languages
English (en)
French (fr)
Inventor
Cees-Nico Verboom
Rainer Oelze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CA2504280A1 publication Critical patent/CA2504280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002504280A 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Abandoned CA2504280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPEP04101578.5 2004-04-16
EP04101578 2004-04-16

Publications (1)

Publication Number Publication Date
CA2504280A1 true CA2504280A1 (en) 2005-10-16

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504280A Abandoned CA2504280A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (https=)
JP (1) JP2007532605A (https=)
CN (1) CN1942180A (https=)
AU (1) AU2005244483B2 (https=)
BR (1) BRPI0509878A (https=)
CA (1) CA2504280A1 (https=)
IL (1) IL178300A0 (https=)
MX (1) MX291518B (https=)
RU (1) RU2387448C2 (https=)
UA (1) UA94693C2 (https=)
WO (1) WO2005110393A1 (https=)
ZA (1) ZA200607794B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE291910T1 (de) * 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen

Also Published As

Publication number Publication date
UA94693C2 (ru) 2011-06-10
CN1942180A (zh) 2007-04-04
AU2005244483A1 (en) 2005-11-24
RU2387448C2 (ru) 2010-04-27
MX291518B (es) 2011-10-31
JP2007532605A (ja) 2007-11-15
RU2006140277A (ru) 2008-05-27
ZA200607794B (en) 2008-05-28
BRPI0509878A (pt) 2007-10-16
WO2005110393A1 (en) 2005-11-24
IL178300A0 (en) 2007-02-11
AU2005244483B2 (en) 2011-06-09
MXPA06011940A (es) 2006-12-15
EP1765319A1 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CN1198608C (zh) 含有必需脂肪酸和生物活性二硫化物的治疗和饮食组合物
KR101336756B1 (ko) 뇌졸중 재발 예방용 조성물
CN1230159C (zh) 必需脂肪酸在预防心血管疾病中的应用
CN101217952B (zh) 用于预防心血管事件发病的组合物
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
JP2006519244A (ja) 糖尿病患者の治療におけるω−３−脂肪酸の使用
WO2010038796A1 (ja) Ｃ型肝炎治療剤
NZ248422A (en) Use of(dihomo-)gamma-linolenic acid (dgla,gla) or linoleic acid(la) to increase gut calcium absorption in humans
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
WO2014179341A1 (en) Treatment with omega-3 fatty acid compositions
EP0517425A1 (en) Fatty acids for the reduction of urinary calcium excretion and the treatment of osteoporosis
IE54558B1 (en) Pharmaceutical composition
CN1280498A (zh) 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用
JP2009544701A (ja) オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
EP2674157A1 (en) Therapeutic agent for diastolic congestive heart failure
WO2014095628A1 (en) Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
JP5043677B2 (ja) アルツハイマー型認知症予防・治療剤
CA2504280A1 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
Eritsland et al. Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile
MX2011001419A (es) Tratamiento a largo plazo de deficiencia cardiaca sintomatica.
JPH04244023A (ja) ω６系不飽和脂肪酸含有薬剤
JP4751257B2 (ja) 心血管イベント発症予防用組成物
JP2020503388A (ja) 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物
JPH09132553A (ja) ドーパミンまたはＬ−ドーパのｎ−３系不飽和脂肪酸誘導体
JPH08310948A (ja) 抗脱毛症剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141014